Inhibitex Expects Neonatal Anti-Infective Veronate To Gain Broad Formulary Coverage
This article was originally published in The Pink Sheet Daily
Executive Summary
Expected American Academy of Pediatrics endorsement will drive utilization, CEO Johnston says. The orphan S. aureus and Candida prophylactic, currently in Phase III, has broader pathogen coverage than potential competitor Nabi’s Altastaph, he maintains. MedImmune’s Synagis will pave the way for acceptance of the antibody, he says.